UNSPSC 51352403: Dienogest/estradiol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352403 Dienogest/estradiol is a Commodity code covering specific pharmaceutical active ingredients and finished formulations that state and local health plans, pharmacy benefit programs, and employee health programs procure through direct manufacturer relationships, cooperative purchasing agreements, and wholesaler-mediated supply chains. State and local buyers under this code include health and human services departments, multistate cooperative purchasing alliances serving state agencies and municipalities, and self-insured employee group health plans. The work solicited ranges from establishing direct-to-manufacturer prescription fulfillment channels that bypass traditional pharmacy benefit managers and group purchasing organizations, to supplying generic and branded formulations through authorized wholesale distributors with detailed compliance, pricing transparency, and supply chain security requirements. Vendors must typically certify current Good Manufacturing Practices compliance, Drug Supply Chain Security Act adherence, maintain relationships with specified wholesalers, and provide competitive pricing across multiple net-price or WAC-based models while managing administrative fees and performance penalties tied to reporting accuracy and delivery timelines.

Recent activity centers on Texas and the multistate cooperative region served by the Minnesota Department of Administration. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for value-based contracting outside traditional PBM and GPO channels—a preliminary phase before formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. The MMCAP procurement requires detailed NDC, SKU, and UPC submissions; 3 percent administrative fees; commercial general liability insurance of $5 million; and dual or multi-award structures based on therapeutic and availability considerations, with performance penalties ranging from $200 to $1,500 per compliance violation.